Skip to main content
. Author manuscript; available in PMC: 2014 Jun 23.
Published in final edited form as: Circ Res. 2014 May 23;114(11):1743–1756. doi: 10.1161/CIRCRESAHA.113.301145

Table 3. Summary of B-Cell Depleting Compounds Already Approved or in Development for Treatment SLE and RA and Their Effects in Experimental Atherosclerosis (if Applicable).

Compound Function Effect on B Cells Effect on Murine Atherosclerosis Clinical Application Reference
α-CD20 Cross-linking of CD20 receptor Fcγ receptor–mediated B-cell depletion Decreased atherosclerosis RA 35
α-BAFF Neutralization of circulating BAFF B2 cell apoptosis Unknown SLE (Belimumab) 135
BAFFR-Fc Neutralization of both circulating and membrane-bound BAFF B2 cell apoptosis Unknown Unknown 136
α-BAFFR BAFF receptor blockage B2 cell apoptosis Decreased atherosclerosis Unknown 31
TACI-Fc Neutralization of circulating and membrane-bound BAFF and APRIL B2 cell and plasma cell apoptosis Unknown Phase 3 clinical trial for SLE (Atacicept) 137,138

APRIL indicates a proliferation inducing ligand; BAFFR, B-cell–activating factor receptor; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; and TACI, transmembrane activator and calcium modulator and cyclophilin ligand interactor.